SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Share-based Payment Arrangement, Expense
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Share-based Payment Arrangement, Expense of -$7.51 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was -$7.51K, a 116.03% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $214.75K, a 574.09% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $134.32K, a 196.67% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $46.85K, a 34.16% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2025 was $932.97K, a 259.19% increase from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2024 was $259.74K, a 42.75% increase from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. share-based payment arrangement, expense for fiscal 2023 was $181.96K.
| Period end | Share-based Payment Arrangement, Expense | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$7.51K 10-Q · filed 2026-09-24 | $27.51K 10-Q · filed 2026-09-24 | |||
| 2025-12-31 | $214.75K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $349.07K derived: sum of 2 quarters · filed 2026-03-31 | $395.92K derived: sum of 3 quarters · filed 2026-09-24 | $932.97K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $134.32K 10-Q · filed 2025-11-13 | $181.17K derived: sum of 2 quarters · filed 2026-09-24 | $718.22K 10-Q · filed 2025-11-13 | $750.08K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-06-30 | $46.85K 10-Q · filed 2026-09-24 | $583.90K 10-Q · filed 2026-09-24 | $615.76K derived: sum of 3 quarters · filed 2026-09-24 | $661.03K derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-03-31 | $537.05K 10-Q · filed 2025-05-08 | $568.90K derived: sum of 2 quarters · filed 2026-03-31 | $614.18K derived: sum of 3 quarters · filed 2026-03-31 | $685.34K derived: sum of 4 quarters · filed 2026-03-31 | |
| 2025-02-27 | $500.00K 10-Q · filed 2026-05-15 | ||||
| 2024-12-31 | $31.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $77.13K derived: sum of 2 quarters · filed 2026-03-31 | $148.29K derived: sum of 3 quarters · filed 2026-03-31 | $259.74K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $45.27K 10-Q · filed 2025-11-13 | $116.44K derived: sum of 2 quarters · filed 2025-11-13 | $227.89K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $71.16K 10-Q · filed 2025-08-13 | $182.61K 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $111.45K 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | $181.96K 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |